'HK must leverage its strengths for biopharma goals'
Health chief Lo Chung-mau said Hong Kong must play to its strengths and support the country's biopharmaceutical innovation and application. Speaking on RTHK's "Vision 15: Hong Kong's Chapter", Lo said the SAR has clear advantages – high‑quality healthcare, a well‑standardised public hospital system and two world‑class medical schools, with a third on the way. He said these are essential for…
Health Secretary Lo Chung-mau emphasized that Hong Kong should capitalize on its strengths to foster the nation's biopharmaceutical innovation and application. Addressing RTHK's "Vision 15: Hong Kong's Chapter," Lo highlighted the territory's advantages, including high-quality healthcare, a well-standardized public hospital system, and two world-class medical schools, with a third under construction.
These factors, essential for medical innovation, position Hong Kong favorably to support the country's biopharmaceutical objectives.
Lo noted that biopharmaceutical research necessitates clinical trials and sufficient patient cases, which Hong Kong currently lacks. To address this, he pointed out that the Greater Bay Area and the entire country can provide the required patient pool. Additionally, he stressed that biopharmaceuticals also require a market, and the Greater Bay Area and the nation offer this advantage.
The government places significant importance on biopharmaceuticals, with mainland biopharmaceutical firms already ranking second globally in innovative drug development. Lo stressed that Hong Kong must leverage its own strengths and collaborate with the country's biopharmaceutical innovation and application efforts.
Written by urgent.news from RTHK English's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- 'HK must leverage its strengths for biopharma goals' news.rthk.hk
